Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
You may also be interested in...
With relatively few new drugs in development for opioid-induced constipation, the category is wide open for new entrants to conduct clinical studies and make a difference for patients; a Market Spotlight report from Datamonitor Healthcare reviews the indication's outlook.
The private US pain specialist and Japanese pharma have partnered for more than a decade to develop novel pain candidates, but despite perhaps slow progress, the level of collaboration has grown with strong communication.
FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.